We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+10.19%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$125B
AUM Growth
+$7.74B
(+6.6%)
Cap. Flow
-$1.18B
Cap. Flow
% of AUM
-0.95%
Top 10 Holdings %
Top 10 Hldgs %
32.47%
Holding
4,267
New
79
Increased
1,134
Reduced
2,614
Closed
100
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Applovin
APP
|
+$80.1M |
| 2 |
Chevron
CVX
|
+$75.4M |
| 3 |
Robinhood
HOOD
|
+$52.2M |
| 4 |
Nutanix
NTNX
|
+$32.2M |
| 5 |
Datadog
DDOG
|
+$29.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$166M |
| 2 |
Apple
AAPL
|
+$150M |
| 3 |
NVIDIA
NVDA
|
+$148M |
| 4 |
HES
Hess
HES
|
+$72.3M |
| 5 |
ANSS
Ansys
ANSS
|
+$59M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.89% |
| 2 | Financials | 13.4% |
| 3 | Consumer Discretionary | 10.96% |
| 4 | Communication Services | 9.45% |
| 5 | Healthcare | 9.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2201
Akebia Therapeutics
AKBA
$252M
| $979K | ﹤0.01% |
358,671
-6,364
| -2% | -$21.2K |
|
2202
Orthofix Medical
OFIX
$419M
| $979K | ﹤0.01% |
66,857
+4,616
| +7% | +$60.6K |
|
2203
Transcat
TRNS
$871M
| $978K | ﹤0.01% |
13,361
-2,810
| -17% | -$226K |
|
2204
American Public Education
APEI
$940M
| $975K | ﹤0.01% |
24,707
-483
| -2% | -$15.3K |
|
2205
Cytek Biosciences
CTKB
$546M
| $973K | ﹤0.01% |
280,367
-2,284
| -0.8% | -$8.57K |
|
2206
Digital Turbine
APPS
$1.74B
| $972K | ﹤0.01% |
151,934
-3,016
| -2% | -$15K |
|
2207
Independent Bank Corp
IBCP
$844M
| $969K | ﹤0.01% |
31,298
-9,152
| -23% | -$296K |
|
2208
RUM Group Inc
RUM
$1.76B
| $969K | ﹤0.01% |
133,839
+17,923
| +15% | +$146K |
|
|
UDMY
2209
DELISTED
Udemy
UDMY
| $967K | ﹤0.01% |
138,008
-14,298
| -9% | -$100K |
|
2210
GSK
GSK
$106B
| $964K | ﹤0.01% |
22,333
+124
| +0.6% | +$4.84K |
|
2211
iShares MSCI Poland ETF
EPOL
$818M
| $962K | ﹤0.01% |
29,874
+500
| +2% | +$16.3K |
|
2212
Arbutus Biopharma
ABUS
$915M
| $961K | ﹤0.01% |
211,784
+3,979
| +2% | +$14.6K |
|
|
TRTX
2213
TPG RE Finance Trust
TRTX
$618M
| $955K | ﹤0.01% |
111,587
-3,559
| -3% | -$31.4K |
|
2214
First Watch Restaurant Group
FWRG
$766M
| $954K | ﹤0.01% |
61,012
-12,870
| -17% | -$224K |
|
2215
EverQuote
EVER
$906M
| $952K | ﹤0.01% |
41,632
-740
| -2% | -$17.9K |
|
2216
Amalgamated Financial
AMAL
$1.49B
| $948K | ﹤0.01% |
34,902
-540
| -2% | -$16K |
|
2217
Carriage Services
CSV
$569M
| $948K | ﹤0.01% |
21,275
-581
| -3% | -$26.3K |
|
2218
Taysha Gene Therapies
TSHA
$1.89B
| $945K | ﹤0.01% |
288,859
+55,603
| +24% | +$157K |
|
|
RYZ
2219
Ryerson Holding Corp
RYZ
$1.46B
| $944K | ﹤0.01% |
41,317
-3
| -0% | -$67 |
|
2220
Cass Information Systems
CASS
$743M
| $944K | ﹤0.01% |
23,993
-2,705
| -10% | -$115K |
|
2221
Nu Skin
NUS
$267M
| $943K | ﹤0.01% |
77,338
-2,781
| -3% | -$29.2K |
|
2222
Malibu Boats
MBUU
$567M
| $942K | ﹤0.01% |
29,029
-1,271
| -4% | -$43.4K |
|
2223
NB Bancorp
NBBK
$989M
| $939K | ﹤0.01% |
53,177
-7,342
| -12% | -$135K |
|
2224
Equity Bancshares
EQBK
$1.05B
| $939K | ﹤0.01% |
23,060
-2,093
| -8% | -$84.7K |
|
2225
Lennar Class B
LEN.B
$20.8B
| $936K | ﹤0.01% |
7,803
-2,195
| -22% | -$260K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2025 Portfolio in Review
As of Q3 2025, RhumbLine Advisers held 4,267 positions worth $125B, up 6.6% from $117B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Trading was light in Q3 2025: portfolio turnover was 4.2%. RhumbLine Advisers opened 79 new positions and exited 100, leaving the 4,267-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Financials and Consumer Discretionary.
- RhumbLine Advisers's largest Q3 2025 buy was The Marzetti Company: 64,390 shares worth $11.1M.
- RhumbLine Advisers added most to Applovin in Q3 2025, an estimated $80.1M increase.
- RhumbLine Advisers's biggest Q3 2025 reduction was Microsoft, cutting an estimated $166M.
- RhumbLine Advisers fully exited Hess in Q3 2025, selling an estimated $72.3M.
- RhumbLine Advisers's ten largest holdings make up 32% of its $125B portfolio in Q3 2025.
- RhumbLine Advisers opened 79 new positions and closed 100 in Q3 2025.
- RhumbLine Advisers's portfolio value rose 6.6% quarter-over-quarter to $125B.
Based on RhumbLine Advisers's 13F filing for Q3 2025, filed 6 Nov 2025.